Reimagining what’s possible for patients living with GA.
Geographic Atrophy
KRIYA.825 is a one-time investigational gene therapy designed to inhibit complement activity, aimed at slowing Geographic Atrophy (GA) lesion growth and vision loss.
GA is the advanced form of dry age-related macular degeneration (dry AMD) and a leading cause of vision loss in older adults. It causes retinal cell damage and cell death, resulting in progressive, permanent loss of sight.
KRIYA.825
How it works
In GA, the inflammation and degeneration are mediated by complement. KRIYA.825 is engineered to deliver genetic instructions encoding a fusion protein (a portion of Complement Receptor 2 fused to a portion of Complement Receptor 1, or CR2-CR1) directly to retinal cells. The CR1 component of the fusion protein is designed to inhibit the complement cascade at the level of C3 and C5 convertase, thereby blocking activation of the alternative and classical complement pathways. The CR2 component is designed to concentrate the activity of the molecule in a targeted manner at the sites of complement deposition on cell surfaces.
Loading…
Failed to load vial.
Specifications
| Indication | Geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) |
|---|---|
| Modality | AAV-based gene therapy |
| Mechanism | Inhibition of complement C3 and C5 pathway activity |
| Payload | CR2-CR1 fusion protein |
| Delivery | Suprachoroidal injection, outpatient |
| Dosing frequency | Single administration |
| Potential patient impact | ~2 million, US and EU |
| Stage | Phase 1/2 |
Disclaimer
Kriya’s durable medicines are investigational and have not been approved as safe or effective by any regulatory health authority.
